Novo Nordisk’s Wegovy is the second drug approved in MASHnews2025-08-18T10:50:09+00:00August 18th, 2025|Endpoints News|
Anocca gets $46M to run early TCR cell therapy clinical trialnews2025-08-18T07:00:20+00:00August 18th, 2025|Endpoints News|
Bayer bets big on KRAS inhibitor; Treg biotech shuts down; Novartis touts trial wins; and morenews2025-08-16T10:00:43+00:00August 16th, 2025|Endpoints News|
Gene therapy startup Kriya Therapeutics gets $313Mnews2025-08-15T20:58:52+00:00August 15th, 2025|Endpoints News|
Kennedy rejects reports of 2028 run, defends top aidenews2025-08-15T19:15:37+00:00August 15th, 2025|Endpoints News|
Pfizer’s sickle cell drug candidate fails Phase 3 trialnews2025-08-15T18:11:26+00:00August 15th, 2025|Endpoints News|
Precigen’s rare disease therapy gets full approval from the FDAnews2025-08-15T15:31:43+00:00August 15th, 2025|Endpoints News|
Neurizon cites ‘strain’ at FDA as reason for delay on IND hold; Fifty Years’ $126M fundnews2025-08-15T14:33:53+00:00August 15th, 2025|Endpoints News|
Which large pharma might make the next move in the VEGF bispecific race?news2025-08-15T11:00:04+00:00August 15th, 2025|Endpoints News|
Stephen Hahn steps down as CEO of Flagship biotech; A new era at AbbVie partner Gubranews2025-08-15T11:00:03+00:00August 15th, 2025|Endpoints News|
